Effects of Hemodialysis on Serum Lipids and Phospholipids of End-stage Renal Failure Patients

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2004 Nov 17

PMID 15543934

Citations 13

Authors

C Piperi

C Kalofoutis

M Tzivras

T Troupis

A Skenderis

A Kalofoutis

Affiliations

Soon will be listed here.

Abstract

Patients with chronic renal failure undergoing periodic maintenance hemodialysis frequently present dyslipoproteinaemia which has been linked to the sharply increased risk of cardiovascular disease in these subjects. Reported defects on lipoprotein-related enzyme activities suggest a possible influence of hemodialysis not just to plasma lipid and lipoprotein levels but also to the composition of cell membranes. In this study, it was investigated whether the reported lipid abnormalities are accompanied by changes in serum phospholipids levels. Blood samples were obtained from 140 patients undergoing maintenance hemodialysis treatment and 122 normolipidemic healthy controls and analyzed for total serum phospholipids and their individual subclasses, as well as for total cholesterol and triglycerides, HDL-cholesterol and its subclasses. A significant decrease was observed in serum HDL cholesterol levels (p < 0.001) and its subclasses, HDL2-cholesterol (p < 0.01) and HDL3-cholesterol (p < 0.01) in patients when compared with healthy controls. A critical increase in the serum triglyceride content (p < 0.001) of patients was also observed. In addition, the serum levels of sphingomyelin (p < 0.01) and diphosphatidylglycerol (p < 0.001) were increased in the patient group, while the levels of phosphatidylcholine (p < 0.01) and phosphatidylinositol (p < 0.01) were significantly decreased in the patient group compared to healthy controls. In conclusion, this work clearly demonstrates that hemodialysis treatment contributes significantly to the dyslipidemic profile of end-stage renal failure patients by altering serum lipoprotein and phospholipids concentrations.

Citing Articles

Sex-Associated Metabolites and Incident Stroke, Incident Coronary Heart Disease, Hypertension, and Chronic Kidney Disease in the REGARDS Cohort.

Couch C, Ament Z, Patki A, Kijpaisalratana N, Bhave V, Jones A J Am Heart Assoc. 2024; 13(9):e032643.

PMID: 38686877 PMC: 11179891. DOI: 10.1161/JAHA.123.032643.

High-coverage targeted lipidomics could reveal lipid alterations and evaluate therapeutic efficacy of membranous nephropathy.

Lu Z, Liu C, Wu Q, Deng Y Nutr Metab (Lond). 2022; 19(1):68.

PMID: 36224633 PMC: 9559911. DOI: 10.1186/s12986-022-00701-4.

Integrative phosphatidylcholine metabolism through phospholipase A in rats with chronic kidney disease.

Wang Y, Zhang Z, Liu H, Guo Z, Zou L, Zhang Y Acta Pharmacol Sin. 2022; 44(2):393-405.

PMID: 35922553 PMC: 9889763. DOI: 10.1038/s41401-022-00947-x.

Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients.

Farouk F, Wahba D, Mogawer S, Elkholy S, Elmeligui A, Abdelghani R Eur J Drug Metab Pharmacokinet. 2019; 45(1):89-99.

PMID: 31667795 DOI: 10.1007/s13318-019-00584-6.

A case series of the dynamics of lipid mediators in patients with sepsis.

Hamaguchi M, Wu H, Tanaka M, Tsuda N, Tantengco O, Matsushima T Acute Med Surg. 2019; 6(4):413-418.

PMID: 31592324 PMC: 6773642. DOI: 10.1002/ams2.443.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Kasiske B . Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S142-56. DOI: 10.1053/ajkd.1998.v32.pm9820472. View

Levey A, Beto J, Coronado B, Eknoyan G, Foley R, Kasiske B . Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998; 32(5):853-906. DOI: 10.1016/s0272-6386(98)70145-3. View

Gillett M, Teixeira V, Dimenstein R . Decreased plasma lecithin:cholesterol acyltransfer and associated changes in plasma and red cell lipids in uraemia. Nephrol Dial Transplant. 1993; 8(5):407-11. View

Wanner C . Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant. 2000; 15 Suppl 5:92-6. DOI: 10.1093/ndt/15.suppl_5.92. View

BARTLETT G . Phosphorus assay in column chromatography. J Biol Chem. 1959; 234(3):466-8. View

Gidez L, Miller G, Burstein M, SLAGLE S, EDER H . Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982; 23(8):1206-23. View

Burstein M, Scholnick H, Morfin R . Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11(6):583-95. View

Jones L, Michell R . The relationship of calcium to receptor-controlled stimulation of phosphatidylinositol turnover. Effects of acetylcholine, adrenaline, calcium ions, cinchocaine and a bivalent cation ionophore on rat parotid-gland fragments. Biochem J. 1975; 148(3):479-85. PMC: 1165566. DOI: 10.1042/bj1480479. View

10.

Ordonez J, Hiatt R, Killebrew E, Fireman B . The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993; 44(3):638-42. DOI: 10.1038/ki.1993.292. View

11.

Koval M, Pagano R . Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta. 1991; 1082(2):113-25. DOI: 10.1016/0005-2760(91)90184-j. View

12.

Kwiterovich Jr P, Sloan H, Fredrickson D . Glycolipids and other lipid constituents of normal human liver. J Lipid Res. 1970; 11(4):322-30. View

13.

Stahl W . Ro le of phospholipids in the NA + ,K + -stimulated adenosine triphosphatase system of brain microsomes. Arch Biochem Biophys. 1973; 154(1):56-67. DOI: 10.1016/0003-9861(73)90034-9. View

14.

Koniger M, Quaschning T, Wanner C, Schollmeyer P, Kramer-Guth A . Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl. 1999; 71:S248-50. DOI: 10.1046/j.1523-1755.1999.07166.x. View

15.

Cano N, LACOMBE P, Stroumza P, Di Costanzo-Dufetel J, Durbec J, Coudray-Lucas C . Perdialytic parenteral nutrition with lipids and amino acids in malnourished hemodialysis patients. Am J Clin Nutr. 1990; 52(4):726-30. DOI: 10.1093/ajcn/52.4.726. View

16.

Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T . Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl. 1999; 71:S227-8. DOI: 10.1046/j.1523-1755.1999.07159.x. View

17.

Das M, HAAK E, Crane F . PROTEOLIPIDS. IV. FORMATION OF COMPLEXES BETWEEN CYTOCHROME C AND PURIFIED PHOSPHOLIPIDS. Biochemistry. 1965; 4:859-65. DOI: 10.1021/bi00881a010. View

18.

Dieplinger H, Schoenfeld P, Fielding C . Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest. 1986; 77(4):1071-83. PMC: 424441. DOI: 10.1172/JCI112406. View

19.

Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H . Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992; 41(6):1653-61. DOI: 10.1038/ki.1992.238. View

20.

Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View